1 / 57

Metformin-Associated Lactic Acidosis At the edge of Death

Metformin-Associated Lactic Acidosis At the edge of Death. By Dr Chan Chin Pang Ian Resident Specialist Department of Intensive Care Unit United Christian Hospital. Diabetes Mellitus (DM). DM represents substantial impact on diabetic patients and their families

akiva
Download Presentation

Metformin-Associated Lactic Acidosis At the edge of Death

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Metformin-Associated Lactic Acidosis At the edge of Death By Dr Chan Chin Pang Ian Resident Specialist Department of Intensive Care Unit United Christian Hospital

  2. Diabetes Mellitus (DM) • DM represents substantial impact on diabetic patients and their families • In 1997, about 10.3 million American had been diagnosed with diabetes-a sixfold increase over the past 4 decades • In 1996, about 67000 diabetes-related amputation were performed • In 1992, $92 billion was spent on diabetes 1. CDC, 1997, 1998

  3. Diabetes Mellitus • Cardiovascular Risk: IHD, CVA, atherosclerosis, aneurysm • Renal risk: nephropathy, end-stage renal failure • Metabolic derangement: hyperglycaemia, DKA, hyperosmolar non-ketotic coma, hyperlipidaemia

  4. Diabetes Mellitus • Diet control • Alpha-Glucosidase Inhibitors (Acarbose, Miglitol) • Sulfonylureas (Glimepiride, Glipizide, Tolbutamide) • Thiazolidinediones (Rosiglitazone) • Biguanides (Metformin, Phenformin) • Insulin

  5. Biguanides Metformin Phenformin Buformin

  6. Metformin-Associated Lactic Acidosis (MALA)

  7. Metformin • Mode of Action Decreases hepatic gluconeogenesis, decreases glucose absorption in the intestines, and increases sensitivity to insulin by increasing peripheral glucose uptake and utilization. • Contraindications Hypersensitivity Renal disease (males with serum creatinine >1.5 mg/dL, females with serum creatinine >1.4 mg/dL) AMI, CHF exacerbation, surgery, or shock Acute or chronic metabolic acidosis • Hutchison TA, Shahan DR, Anderson ML (eds): DRUGDEX System. MICROMEDEX, Inc, Englewood, Colo. (Edition expires 12/2000) • Hebel SK, Katstrup EK (eds): Drug Facts and Comparisons. St. Louis, Mo. 2001 • For conversion of creatinine expressed in conventional units to SI units, multiply by 88.4

  8. Metformin-Associated Lactic Acidosis • Incidence: 0.03 cases/1,000 patient-years (Phenformin, another biguanide introduced into the market around 1950, 10 to 20 times greater risk of developing lactic acidosis, especially the Whites, probably due to its long side chain, which enhances its lipophilicity and results in a greater affinity for binding to mitochondrial membranes, which could account for its greater ability to inhibit aerobic metabolism than metformin)

  9. Metformin-Associated Lactic Acidosis • Mortality: about 50% of cases • Sign and symptoms: non-specific (nausea, vomiting, altered consciousness, fatigue, abdominal pain, and thirst) 1.Gowardman JR. Fatal metformin induced lactic acidosis: case report. N Z Med J 1995;108:230-11. 2.Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med 1992;152:2333-6. 3.Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9. 4.Lee AJ. Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 1996;16:327-51.

  10. Grave Prognosis? 19th century Hospital www.iconsofeurope.com/tb2005.htm

  11. Metformin-Associated Lactic Acidosis Local Data?

  12. Local Experience on Metformin-Associated Lactic Acidosis (MALA): Retrospective Case Review

  13. Objective of the Review • To review demographic data, dosage of metformin, initial presentation, physiological parameters and clinical outcome of patients suffering from MALA and required ICU care. • Life-threatening events, such as unstable arrhythmia, cardiac arrest and treatment would be recorded. • Expected mortality rates for APACHE II scores would be compared with the observed mortality rates.

  14. Data Collection • Intensive Care Unit, United Christian Hospital • 1/12/2004 to 1/12/2006 • Clinical Data and Reporting System (CDARS) • Clinical Management System (CMS)

  15. Data Collection • Searching Criteria -1/12/2004 to 1/12/2006 and ICU patient and metformin AND one of the followings -renal failure, acute renal failure, acute-on-chronic renal failure, renal impairment -hyperkalaemia -metabolic acidosis -lactic acidosis -CVVH -HD

  16. Inclusion Criteria • In-patient between 1/12/2004 and 1/12/2006 • UCH ICU Admission • Age >/=18 • On metformin • Metabolic Acidosis (pH<7.35; HCO3<22mmol/L) • Raised anion gap (>14mmo/L) • Serum lactate > 5mmol/L • Acute or Acute on chronic renal failure

  17. For conversion of creatinine expressed in conventional units to SI units, multiply by 88.4 Assessment of the RIFLE Criteria for Acute Renal Failure in Hospitalized Patients Crit Care Med. 2006;34(7):1913-1917. Bellomo, Ronco, et al

  18. Distribution and hospital mortality for each RIFLE criterion in all patients. N indicates the number of patients in each RIFLE category. The straight line indicates the mortality rate for each category. The different headings along the x-axis indicate the various RIFLE groups from normal to renal failure. Fx3 indicates patients with renal failure and with a three-fold increase in creatinine, and Fc indicates patients with renal failure and with a creatinine >400 μmol/L that has not increased three-fold.

  19. Bowel ischemia Severe iron-deficiency anemia Liver disease Alcoholic ketoacidosis Pancreatitis Malignancy Status epilepticus Heat stroke Carbohydrate malabsorption syndromes MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and strokelike episodes) Drug/ Toxin other than metformin 1. Acetaminophen 2. Alcohols and glycols (ethanol, ethylene glycol, methanol, propylene glycol) 3. Antiretroviral nucleoside analogs 4. Cyanogenic compounds Exclusion Criteria

  20. Measurement and Result

  21. Sample Characteristics • Identified 9 cases • 3 Males and 6 Females • Mean Age 68.6 +/- 5.6 • ADL: 8 independent and 1 partially dependent • Mean BW (kg) 52.7 +/- 11.9 (Range 33kg-68kg) • 1 patient with pre-existing proteinuria • 1 patient with pre-existing retinopathy

  22. Sample Characteristics

  23. Medications • Metformin:*Mean dose (g/day): 2.25+/-0.93 (range:1-3) *6/9 (67%) patients had been put on metformin for >1 year *All patients had been put on metformin for > 0.5 year *All (100%) without dosage change in 3 months before admission

  24. Medications • 7 patients on combination oral therapy for DM (Sulfonylureas) • None on insulin • None on ARB • 4 patients on ACEI (Not max. dose) • 2 patients on loop or thiazide diuretics

  25. Blood Glucose Control • 4 patients’ FBS not a/v

  26. Presentation • GI symptoms: 8/9 (89%) Nausea, vomiting, diarrhea, abdominal pain • Shortness of breath: 4/9 (44%) • Refuse feeding: 2/9 (22%) • Dizziness: 2/9 (22%) • Hypoglycaemia: 1/9 • Generalized weakness: 1/9 • 7/9 (78%) had symptoms for 1 day only

  27. Patient Presentation Non-specific Multiple complaint

  28. Precipitating Event • 7/9 (78%) had identifiable precipitating event • 4/9 (44%) had sepsis

  29. Admission • 7/9 patients were admitted to ICU directly from AED

  30. Neurological Status • 4/9 patients with GCS<15

  31. Worst RFT within 24 hr ICU admission in MALA Patients • One of the patients had K ~9.71 at AED

  32. Worst RFT within 24 hr ICU admission in MALA Patients • One of the patients had K ~9.71 at AED

  33. Worst Blood Gas within 24 hr ICU admission in MALA Patients

  34. Serum Lactate Level

  35. Input and Output • The one with minimal fluid intake was suffering from decompensated CCF

  36. Input and Output • The one with minimal fluid intake was suffering from decompensated CCF

  37. Haemodynamic Parameter • 5/9 patients on inotropic support • 1/9 patients developed pulseless VT, successfully aborted by defibrillation and resuscitation, the patient is alive

  38. Inotropic Support • 5/9 patients required inotropic support • 3/9 patients required one inotrope • 2/9 patients required multiple inotropes • Inotropes included dopamine, adrenaline, noradrenaline

  39. Sodium Bicarbonate • 7/9 (78%) Patients were given NaHCO3 • NaHCO3 was given either at AED/ ICU or both • 1 patient record not a/v

  40. No significant changes of blood pH (P = 0.055) and HCO3 (P = 0.141) after NaHCO3 infusion

  41. Organ Support • All patients received CVVH • 3/9 patients required IPPV >96 hr • 1/9 patient received NIPPV

  42. Discharge Diagnosis

  43. Patients Outcome • Mean LOS ICU (Day) 7.9+/-6.6 (2-23) • Mean LOS Hospital (Day) 15.9+/-11.8 (3-42) • Mean Cr on discharge 123.5+/-27.5 (82-161) • Cr of 5 patients become within reference range • None is dialysis-dependent

  44. Patients Outcome • 1 patient died Cause of death: MOF/ Pneumonia Troponin T 82.2 • Mean predicted mortality rate is 67.5% Vs Observed mortality rate 11%

  45. MALA Discussion

  46. Discussion • Elderly with age more than 65 years old • Female seems commoner • Premorbid renal function is usually normal • Polypharmacy • Metformin daily dose not less than 1g • Recent initiation or change of dose of metformin may not be essential for the development of MALA

  47. Discussion • MALA presentations are usually non-specific and subtle. GI symptoms and respiratory compensatory response to severe metabolic acidosis seem dominant • The onset of symptom is often abrupt (e.g. 1-2 days)

  48. Discussion • Usually, precipitating causes can be identified • Sepsis is not uncommon in MALA • Patients with MALA are usually very ill with high APACHE II score, elevated Cr and blood lactate level and require organ support, such as IPPV, CRRT, inotropes • Patients with MALA can deteriorate suddenly if decompensation or unstable arrhythmia develop

  49. Discussion • The role of NaHCO3 infusion is still controversial, needs to balance between potential benefit and risk • It may be considered in severe metabolic acidosis while waiting for CRRT • No significant changes of blood pH and HCO3 after NaHCO3 infusion was demonstrated in this review 1.Horacio J. Adrogue, M.D., and Nicolaos E. Madias, M.D. Management of Life-Threatening Acid–Base Disorders— First of Two Parts. N Eng J Med Volume 338:26-34 January 1, 1998 Number 1

More Related